Bioceres Crop Solutions Earnings Call Transcripts
Fiscal Year 2026
-
Fiscal Q3 2026 saw a 23% revenue decline and a $10 million net loss, driven by lower gross profit and the impact of the ProFarm foreclosure, which resulted in a $179 million non-cash loss. Management is focused on liquidity, legal disputes, and streamlining operations.
-
Revenue fell 17% year-over-year to $77.5 million, but gross margin expanded to 47% and adjusted EBITDA rose 61% due to cost reductions. Segment margins improved, though seed and crop protection revenues declined. Net debt remained stable amid ongoing debt dispute.
Fiscal Year 2025
-
Fiscal 2025 saw a 28% revenue decline and margin compression due to macroeconomic headwinds in Argentina and a strategic shift in the seed business. Cost controls, working capital improvements, and international growth in core technologies are expected to support recovery and margin expansion as the company transitions to a more scalable model.
-
Q3 saw lower revenue and profit due to the absence of last year's Syngenta payment, but cash flow improved by $40 million year-over-year through working capital efficiencies and seed business restructuring. The company is positioned for growth with the RinoTec launch and ongoing cost reductions.
-
Quarterly revenues fell 24% year-over-year due to Argentina's market contraction, but gross margin improved to 42%. The company is shifting to an asset-light, royalty-based model, forming new partnerships and focusing on cost efficiency and global expansion.
-
Q1 revenue fell 20% year-over-year due to drought in Argentina, but gross margin improved to nearly 40%. International growth, regulatory wins, and a strategic shift in HB4 commercialization support optimism for the rest of the year.
Fiscal Year 2024
-
Record revenues and EBITDA were achieved despite challenging agricultural markets and declining crop prices. HB4 and biologicals drove growth, with a strategic pivot to a more conventional HB4 model and new leadership to accelerate expansion. Focus for 2025 is on profitability, cash generation, and regulatory progress.